醫藥品·生物科技的分銷交易 (2016～2024年)

本報告提供全球醫藥品·生物科技市場上分銷交易的締結狀況相關分析，彙整整體交易數量的轉變和預測 (2016～2024年)，近幾年的代表性交易案例，主要企業的交易締結動向，各技術·各治療領域達成交易的動向等資訊，為您概述為以下內容。

目錄

摘要整理

第1章 簡介

第2章 分銷交易趨勢

• 簡介
• 分銷交易定義
• 分銷交易趨勢 (2016年以後)
  • 分銷交易趨勢:各年度 (2016～2024年)
  • 分銷交易趨勢:各開發階段 (2016～2024年)
  • 分銷交易趨勢:各產業領域 (2016～2024年)
  • 分銷交易趨勢:各治療領域 (2016～2024年)
  • 分銷交易趨勢:各技術種類 (2016～2024年)
  • 分銷交易趨勢:最活躍的企業的情況 (2016～2024年)
  • 純分銷交易的屬性
  • 多零組件交易上的流通屬性
• 締結商業聯盟以履行分銷合約

第3章 分銷交易結構:概要

• 簡介
• 流通契約結構
• 更廣泛的聯盟契約一部分的銷售權

第4章 主要分銷交易

• 簡介
• 前幾名的分銷交易 (以金額為準)

第5章 分銷交易:最活躍的交易締結25企業

• 簡介
• 分銷交易:最活躍的交易締結25企業

第6章 分銷交易:契約的明細

• 簡介
• 分銷交易的契約數量 (2016～2024年)
• 交易明細
• 交易明細:流通的交易締結，企業名 (A～Z)
• 交易明細:流通的交易締結，各治療領域
• 交易明細:流通的交易締結，各技術種類

關於Wildwood Ventures

Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals.

Fully revised and updated, the report provides details of distribution deals from 2016 to 2024.

The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of distribution deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals.

Chapter 4 provides a review of the leading distribution deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

The deal directory includes a comprehensive listing of all distribution deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Key benefits

Distribution Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse distribution deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Distribution Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Deals in Pharmaceuticals and Biotechnology includes:

• Trends in distribution dealmaking in the biopharma industry
• Overview of distribution deal structure
• Directory of distribution deal records covering pharmaceutical and biotechnology
• The leading distribution deals by value
• Most active distribution dealmakers
• The leading distribution partnering resources

In Distribution Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Distribution Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for distribution deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

• 2.1. Introduction
• 2.2. Definition of distribution deals
• 2.3. Trends in distribution deals since 2016
  • 2.3.1. Distribution dealmaking by year, 2016 to 2024.
  • 2.3.2. Distribution dealmaking by phase of development, 2016 to 2024.
  • 2.3.3. Distribution dealmaking by industry sector, 2016 to 2024.
  • 2.3.4. Distribution dealmaking by therapy area, 2016 to 2024.
  • 2.3.5. Distribution dealmaking by technology type, 2016 to 2024.
  • 2.3.6. Distribution dealmaking by most active company, 2016 to 2024.
  • 2.3.7. Attributes of pure distribution deals
  • 2.3.8. Attributes of distribution in multi-component deals
• 2.4. Aligning partners to make the distribution agreement workChapter

Chapter 3 - Overview of distribution deal structure

• 3.1. Introduction
• 3.2. Distribution agreement structure
• 3.3. Distribution rights as part of a wider alliance agreement

Chapter 4 - Leading distribution deals

• 4.1. Introduction
• 4.2. Top distribution deals by value

Chapter 5 - Top 25 most active distribution dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active distribution dealmakers

Chapter 6 - Distribution deals including contracts directory

• 6.1. Introduction
• 6.2. Distribution deals with contracts 2016-2024
• Deal directory
• Deal directory - distribution dealmaking by companies A-Z
• Deal directory - distribution dealmaking by therapy area
• Deal directory - distribution dealmaking by technology type

About Wildwood Ventures

• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of distribution
• Figure 2: Trends in distribution deal announcements, 2016 to 2024
• Figure 3: Distribution deals signed at each phase of development, 2016 to 2024
• Figure 4: Distribution deals by industry sector, 2016 to 2024
• Figure 5: Distribution deals by therapy area, 2016 to 2024
• Figure 6: Distribution deals by technology type, 2016 to 2024
• Figure 7: Top 25 most active distribution dealmakers, 2016 to 2024
• Figure 8: Issues in implementing distribution agreements
• Figure 9: Distribution agreements - what should a contract include?
• Figure 10: Components of the distribution deal structure
• Figure 11: Top distribution deals by value 2016 to 2024
• Figure 12: Most active distribution dealmakers 2016 to 2024